| NCCN International Prognostic Index (NCCN-IPI) – Prognostic index for diffuse large B cell lymphoma |
| NCCN-IPI | Score |
|---|---|
| Age, y | |
| >40 to ≤60 | 1 |
| >60 to ≤75 | 2 |
| >75 | 3 |
| LDH, normalized | |
| >1 to ≤3 | 1 |
| >3 | 2 |
| Ann Arbor stage III-IV | 1 |
| Extranodal disease-Disease in bone marrow, CNS, liver/GI tract, or lung. | 1 |
| Performance status ≥2 | 1 |
Risk group and prognosis
| NCCN-IPI score | Risk group | DLBCL 5 year OS |
|---|---|---|
| 0 – 1 | Low | 96% |
| 2 – 3 | Low-intermediate | 82% |
| 4 – 5 | High-intermediate | 64% |
| ≥ 6 | High | 33% |
- The clinically based NCCN-IPI is a robust prognostic tool for the rituximab era that better discriminates low- and high-risk DLBCL patients compared with the IPI. The NCCN-IPI outperforms the IPI by refined categorization of age and LDH, and the identification of disease involvement at specific extranodal sites.
- The NCCN-IPI derives from multivariate analysis of survival of 1650 patients with newly-diagnosed de novo diffuse large B cell lymphoma treated between 2000 and 2010 at seven US National Comprehensive Cancer Network (NCCN) centers. (Link to original article)